C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in C4 Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- +8 vs. Q3 2025
- Shares held
- 79.8M
- +27.5M (+52.4%) vs. Q3 2025
- Total value
- $152.5M
- +$36.2M (+31.2%) vs. Q3 2025
- New holders
- 24
- 43 more added
- Sold out
- 16
- 20 more reduced
4 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 9,439,328 | $18.0M | 0.03% | +9,439,328 | New |
| Tang Capital Management LLC | 0 | $0 | 0.00% | −900,000−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −503,145−100.0% | Sold out |
| Shay Capital LLC | 0 | $0 | 0.00% | −420,000−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −106,300−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −82,509−100.0% | Sold out |
| Voleon Capital Management LP | 0 | $0 | 0.00% | −28,420−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −20,510−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −19,146−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −14,889−100.0% | Sold out |
| Zacks Investment Management | 0 | $0 | 0.00% | −13,043−100.0% | Sold out |
| National Asset Management, Inc. | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| JFS Wealth Advisors, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Wealthspire Advisors, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −74−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −146−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Point72 Asia (Singapore) Pte. Ltd. | – | – | – | – | Not filed |
| Wolverine Trading, LLC | – | – | – | – | Not filed |
| Point72 (DIFC) Ltd | – | – | – | – | Not filed |